>Dew, I know you’re not too fond of my bullish view of Peregrine’s Anti-PS mab, Bavituximab, for the treatment of enveloped viruses (incl. HepC) and solid cancers, but I think it’s fair to offer a differing opinion to yours<
No problem, but I’ll note that Big Pharma appears to agree with me on the unattractiveness of this compound. Regards, Dew
Market Data 
Markets 
AI
